VIVEVE MEDICAL, INC. VIVE Cash Flow

Viveve medical, inc. (VIVE)

CashFlow / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Jun'14	Mar'14	Dec'13	Sep'13	Jun'13	Mar'13	Dec'12	Sep'12	Jun'12	Mar'12	Dec'11	Sep'11	Jun'11	Mar'11
Cash flows from operating activities:
Net loss
-38,807	-42,526	-41,201	-45,549	-47,341	-49,981	-46,713	-44,024	-42,933	-36,959	-32,555	-27,809	-22,700	-20,111	-17,968	-16,318	-14,008	-12,426	-10,491	-9,777	-7,902	-6,180	-5,322	-6,387	2,689	-4,317	0	0	0	-	-	-	-	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Provision for doubtful accounts
991	1,028	336	332	248	179	-118	-189	-179	-221	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net income (loss)
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-8,387	-12,417	-9,652	-8,750	-5,758	0	0	0
Income from discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	53	0	0	0
Gain on sale of discontinued operations, net of taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	687	0	0	0
Depreciation and amortization
1,189	1,177	1,060	999	947	786	676	595	492	449	351	254	197	111	98	86	81	77	71	63	58	56	72	69	68	66	47	49	48	43	37	25	15	9	0	0	0
Stock-based compensation
2,614	2,400	2,375	2,623	2,778	3,035	2,852	2,574	2,253	1,872	1,672	1,457	1,204	1,020	737	520	366	220	185	244	213	184	164	40	32	87	177	322	390	544	458	354	340	148	0	0	0
Fair value of warrants issued
-	-	-	-	-	-	-	-	-	-	-	-	-	162	261	33	131	251	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Revaluation of fair value of warrant liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-52	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Non-cash interest expense
1,305	1,577	1,670	1,647	1,593	1,580	1,463	1,336	1,400	1,049	796	558	446	456	468	482	194	197	199	256	343	418	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets and accretion of operating lease liabilities
0	5	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Loss from minority interest in limited liability company
-684	-627	-549	-513	-533	-657	0	0	0	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Changes in assets and liabilities:
Change in fair value of warrant and options liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-2,439	-808	0	0	0
Change in fair value of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,302	-936	-2,024	-4,272	-3,139	-2,076	-1,894	0	0	0
Loss on extinguishment of convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Financing costs associated with convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	530	0	0	0
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Non-cash interest expense
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0
Deferred income taxes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	492	0	0	0
Accounts receivable
-2,508	-3,103	-1,849	-3,353	-1,973	-330	40	3,252	2,800	3,901	3,026	3,211	3,229	1,498	1,568	589	756	587	0	0	0	-	-	-	-	-1	10	-104	79	-48	0	0	0	-	-	-	-
Inventory
963	1,070	-95	355	283	1,986	2,806	2,349	1,604	67	891	1,564	1,820	1,237	828	533	779	1,438	528	169	-39	-97	-162	-90	-22	-71	-52	-39	-157	-56	33	46	-59	-72	0	0	0
Prepaid expenses and other current assets
-913	-111	371	-256	-185	-183	-537	1,136	2,062	1,675	1,919	684	-302	-162	88	-43	1,187	879	1,022	924	72	41	-86	230	-265	243	163	14	317	-58	-164	-261	50	-66	0	0	0
Other noncurrent assets
-440	-40	-70	-57	-50	-31	89	56	52	66	-21	-7	6	-2	-13	-14	-14	-18	116	123	130	112	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable
-422	-2,386	-1,711	-3,261	-1,181	-805	-67	1,523	506	1,713	1,092	1,490	1,730	1,654	1,376	1,242	1,017	1,016	535	-592	-431	-551	-358	664	597	482	585	15	208	228	186	369	-97	-194	0	0	0
Deferred revenue
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-205	-37	32	0	0	0	-	-	-	-
Accrued and other liabilities
-1,988	-1,536	-925	-228	307	2,143	1,174	3,059	2,152	2,419	2,008	178	-268	1,192	1,397	1,310	2,071	1,070	600	804	456	57	-18	-153	-72	-160	15	189	4	161	70	-3	46	-36	0	0	0
Other noncurrent liabilities
-691	-599	400	433	468	502	512	500	323	274	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net cash used in operating activities
-25,414	-31,236	-35,707	-39,110	-39,457	-43,090	-41,824	-40,756	-41,995	-34,853	0	0	0	-	-	-	-12,570	-12,195	-10,268	-9,708	-7,091	-5,991	-4,857	-2,240	-2,171	-3,755	0	0	0	-	-	-	0	-	-	-	0
Cash flows from investing activities:
Proceeds from sale of property and equipment
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Purchase of property and equipment
1,069	1,087	2,007	2,057	1,859	2,142	1,078	1,308	1,216	905	842	519	371	256	285	245	145	109	0	0	0	-	-	-	-	-	-	-	-	74	0	0	0	-	-	-	-
Net cash used in investing activities
-1,069	-1,087	-2,007	-2,057	-1,859	-2,142	-1,078	-3,808	-3,716	-3,405	0	0	0	-	-	-	-145	-109	0	0	0	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Proceeds from equity financings, net of issuance costs
-	-	-	-	-	53,792	33,532	33,521	33,298	31,565	31,440	31,469	45,389	13,886	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Transaction costs in connection with November 2019 Offering
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of stock options
-	-	-	-	-	-	-	-	-	-	-	-	-	14	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from exercise of Series A and B common warrants
0	-	-	-	-	-	-	-	-	-	-	-	-	92	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net proceeds from sale of common stock and warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Proceeds from related party convertible bridge notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	3,605	0	0	0
Repayments of note payable
-	-	-	-	-	-	-	-	-	-	-	-	-	4,833	0	0	0	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common shares from employee stock purchase plan
-	56	101	164	203	233	264	200	141	76	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from related party convertible bridge notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,500	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	25,238	17,500	18,769	14,412	17,863	7,373	6,573	6,578	1,236	186	3,740	0	0	0	-	-	-	-	-	-	-	-
Net cash provided by financing activities
17,704	16,108	26,703	20,460	20,759	54,025	43,792	43,717	52,700	50,902	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Net cash provided by operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	210	0	0	0
Net cash provided by investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,000	0	0	0
Net cash provided by discontinued operations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,210	0	0	0
Effect of exchange rate changes on cash and cash equivalents
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	16	67	0	0	0
Net decrease in cash and cash equivalents
-8,779	-16,215	-11,011	-20,707	-20,557	8,793	890	-847	6,989	12,644	5,196	11,129	26,383	726	7,950	11,569	4,785	6,465	4,085	8,143	165	465	1,615	-1,100	-1,998	-19	0	0	0	-	-	-	-3,657	1,261	0	0	0
Supplemental disclosure:
Cash paid for interest
-	2,508	2,749	2,722	2,695	2,673	2,438	2,198	2,525	2,066	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	681	598	225	196	183	164	149	149	151	99	114	141	169	229	229	217	203	199	199	171	0	0	0
Cash paid for income taxes
-	-	-	-	-	-	-	-	-	-	0	0	1	1	1	1	0	1	1	1	1	1	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-
Supplemental disclosure of cash flow information as of end of period:
Issuance of Series B convertible preferred stock in settlement of dividends
0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted stock awards granted to employees for 2015 accrued bonuses
-	-	-	-	-	-	-	-	-	-	-	-	-	246	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashless settlement of warrants
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	-	-	-	-	-	-	-	-
Issuance of note payable in settlement of accrued interest
1,034	1,226	1,295	1,282	1,269	1,256	1,144	1,111	800	495	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net transfer of equipment between inventory and property and equipment
250	207	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted stock awards granted to employees for 2015 accrued bonuses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net transfer of equipment between inventory and property and equipment
-	-	-	-	-	-	-	-	159	364	401	366	363	99	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating cash outflows from operating leases
297	295	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use assets obtained in exchange for operating lease liabilities (upon adoption of ASC 842)
-	629	0	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Convertible notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0